SZL P1-41

Research use only, not for human use.

A small molecule Skp2 E3 ligase inhibitor that prevents Skp2-Skp1 interaction and Skp2 SCF E3 ligase activity in vitro.

A small molecule Skp2 E3 ligase inhibitor that prevents Skp2-Skp1 interaction and Skp2 SCF E3 ligase activity in vitro; specific diminishes E3-ligase activity of Skp2-SCF complex, but not of other F-box SCF complex; inhibits Skp2-mediated p27 ubiquitination, induced endogenous p27 protein expression in prostate cancer cells; exhibits potent antitumor activities in multiple animal models and cooperates with chemotherapeutic agents to reduce cancer cell survival.

SZL P1-41 (5-20μM; 24 hours) induces endogenous p27 protein expression in PC3 cells and also induced expression of p21, another Skp2 substrate.

SZL P1-41 (40-80 mg/kg; i.p.) displays a potent effect on inhibiting prostate and lung tumor growth in Nude mice bearing A549 and PC3 tumor xenografts.

SZL-P1-41 | SZL P1 41 | SZLP141 | SKP2 E3 Ligase Inhibitor III

Proteasome/Ubiquitin

E3 Ubiquitin Ligase

Skp2

Cancer

——

222716-34-9

420.524

C24H24N2O3S

>98% (HPLC)

10 mM in DMSO

O=C1C(C2=NC3=CC=CC=C3S2)=COC4=C(CN5CCCCC5)C(O)=C(CC)C=C14

4H-1-Benzopyran-4-one, 3-(2-benzothiazolyl)-6-ethyl-7-hydroxy-8-(1-piperidinylmethyl)-

(-20℃)

With Ice Pack

≥ 2 years